Last edition
News about "congenital adrenal hyperplasia "
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Congenital Adrenal Hyperplasia | 19/01/2026 | By News Bureau | 104
Neurocrine Biosciences Secures FDA Approval of CRENESSITY
CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction.
Congenital Adrenal Hyperplasia | 16/12/2024 | By Aishwarya | 178
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy